Walton Duncan C, Cantwell Linda, Hiho Steven, Ta Joseph, Wright Stephen, Sullivan Lucy C, Snell Greg I, Westall Glen P
Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia.
Lung Transplant Service, Alfred Hospital, Melbourne, Australia; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Transpl Immunol. 2018 Dec;51:73-75. doi: 10.1016/j.trim.2018.10.002. Epub 2018 Oct 12.
The use of algorithms such as HLAMatchmaker to redefine donor-recipient HLA matching is gaining increasing attention. Our research has previously demonstrated that higher HLA class II eplet mismatches correlated with the development of chronic lung allograft dysfunction (CLAD). In this study of lung transplant recipients we prospectively examined the association between donor-recipient HLA eplet mismatches as defined by HLAMatchmaker (version 2.1) and de-novo anti-HLA donor-specific antibody (DSA) formation, as assessed by single antigen-bead solid phase assay. HLA class II eplet mismatch, when split at the median for the cohort, predicted the development of de-novo HLA class II DSA at 3 months but not at 12 months. Having previously shown that high HLA class II eplet mismatches was associated with CLAD, we now show that the same factors are associated with de-novo HLA class II DSA post-transplant.
使用诸如HLAMatchmaker等算法来重新定义供体 - 受体HLA匹配正受到越来越多的关注。我们之前的研究表明，较高的HLA II类表位错配与慢性肺移植功能障碍（CLAD）的发生相关。在这项针对肺移植受者的研究中，我们前瞻性地研究了由HLAMatchmaker（2.1版）定义的供体 - 受体HLA表位错配与通过单抗原珠固相分析评估的新生抗HLA供体特异性抗体（DSA）形成之间的关联。当按队列中位数划分时，HLA II类表位错配可预测3个月时新生HLA II类DSA的发生，但不能预测12个月时的情况。我们之前已表明高HLA II类表位错配与CLAD相关，现在我们表明相同的因素与移植后新生HLA II类DSA相关。
